Clinical Trials Logo
  1. Home
  2. Migraine
  3. NCT00335803
  4. Details
NCT00335803 Clinical Trial

A Research Study To Compare Two Kinds Of Daily Headache

Migraine Clinical Trial

Official title:
A Comparison Of Subjects With New Daily Persistent Headache (NDPH) And Subjects With Transformed Migraine (TM)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00335803
Other study ID # WBY/NDPH-TM/001
Secondary ID
Status Completed
Phase N/A
First received June 9, 2006
Last updated January 22, 2009
Start date March 2006
Est. completion date September 2007

Study information
Verified date January 2009
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Chronic daily headache has been classified into several categories. One category is of sudden onset and is called New Daily Persistent Headache (NDPH). Another category of daily headache evolves gradually and is called Transformed Migraine (TM). This research study is being conducted to compare people with these two kinds of daily headache in order to improve our understanding of these conditions.

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date September 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 14 Years to 65 Years
Eligibility Inclusion Criteria:

- Male and female patients aged 14-65, inclusive

- Diagnosis of NDPH or TM according to the Silberstein-Lipton criteria.

- Ability to read and understand an informed consent form and study procedures

Exclusion Criteria:

- Pregnancy

- Subjects with any disease or condition that would result in unreliable data or confound the data obtained for this study, as determined by the principal investigator.

Study Design

N/A

Related Conditions & MeSH terms

Locations
Country Name City State
United States Jefferson Headache Center Philadelphia Pennsylvania

Sponsors (1)
Lead Sponsor Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A